Compare VFS & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFS | GRFS |
|---|---|---|
| Founded | 2017 | 1940 |
| Country | Vietnam | Spain |
| Employees | N/A | 23800 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 6.5B |
| IPO Year | N/A | N/A |
| Metric | VFS | GRFS |
|---|---|---|
| Price | $3.27 | $8.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | $5.83 | ★ $10.15 |
| AVG Volume (30 Days) | 260.1K | ★ 446.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.54% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.47 |
| Revenue Next Year | $53.71 | $4.92 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.56 | $6.19 |
| 52 Week High | $3.82 | $11.14 |
| Indicator | VFS | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 42.21 |
| Support Level | $3.17 | $8.66 |
| Resistance Level | $3.38 | $9.11 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 34.21 | 42.28 |
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Car, E-scooter and Ebus. The Car segment includes the design, development, manufacturing and sales of cars and related battery lease and battery charging services for cars. The E-scooter segment includes the design, development, manufacturing and sales of e-scooters and related battery lease and battery charging service for e-scooters. The Ebus segment includes the design, development, manufacturing and sales of Ebus.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.